Knopp Biosciences LLC is a privately held company managing a portfolio of equity securities and future product royalties. Founded in 2004, the company enjoyed an 18 year record of drug discovery in challenging immunological and neurological diseases.
Knopp’s clinical-stage oral small molecule, dexpramipexole, is currently being developed for eosinophilic asthma by Areteia Therapeutics, Inc. (www.areteiatx.com), a portfolio company of Bain Capital Life Sciences. Knopp’s clinical stage Kv7 platform, small-molecule treatments for epilepsy and other hyperexcitability disorders, has been acquired and is being advanced by Biohaven Pharmaceuticals (www.biohavenpharma.com).
Coming Spring 2023 — Knopp members will be invited to the new investor portal to view the company's latest newsletters, financial statements, and other proprietary information.
For immediate inquiries, e-mail investor relations
© Copyright 2022 Knopp Biosciences LLC. All Rights Reserved